VERTEX PHARMACEUTICALS INC / MA Net Cash Provided by (Used in) Financing Activities in USD from Q1 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2010 to Q1 2025.
  • Vertex Pharmaceuticals Inc / Ma Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was -$680M, a 90.3% decline year-over-year.
  • Vertex Pharmaceuticals Inc / Ma annual Net Cash Provided by (Used in) Financing Activities for 2024 was -$1.49B, a 166% decline from 2023.
  • Vertex Pharmaceuticals Inc / Ma annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$562M, a 730% decline from 2022.
  • Vertex Pharmaceuticals Inc / Ma annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$67.7M, a 95.4% increase from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$680M -$323M -90.3% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q1 2024 -$358M -$62.8M -21.3% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q1 2023 -$295M -$199M -209% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q1 2022 -$95.4M +$423M +81.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q1 2021 -$519M -$159M -44.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q1 2020 -$359M -$317M -756% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q1 2019 -$42M -$121M -153% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-01
Q1 2018 $79M +$369M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-01
Q1 2017 -$290M -$294M -6258% Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-27
Q1 2016 $4.7M -$45.7M -90.7% Jan 1, 2016 Mar 31, 2016 10-Q 2017-04-28
Q1 2015 $50.4M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-03
Q1 2011 -$16.4M -$24M -314% Jan 1, 2011 Mar 31, 2011 10-Q 2011-05-06
Q1 2010 $7.64M Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-06

VERTEX PHARMACEUTICALS INC / MA Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$1.49B -$933M -166% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-13
2023 -$562M -$495M -730% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-13
2022 -$67.7M +$1.41B +95.4% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-13
2021 -$1.48B -$973M -193% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 -$505M -$632M -499% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-10
2019 $127M +$198M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-09
2018 -$71.2M -$140M -204% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-11
2017 $68.4M -$64.9M -48.7% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-13
2016 $133M -$55.6M -29.5% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-13
2015 $189M Jan 1, 2015 Dec 31, 2015 10-K 2018-02-15
2010 $425M Jan 1, 2010 Dec 31, 2010 10-K 2011-02-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.